Retatrutide is an experimental triple receptor agonist (GLP-1 + GIP + glucagon) developed by Eli Lilly. Phase 2 trials showed up to 24% body weight reduction after 48 weeks — surpassing semaglutide (15%) and tirzepatide (21%) — with 100% of participants at the highest dose achieving at least 5% weight loss. Currently in Phase 3 trials with expected FDA approval in 2026-2027.
What Is Retatrutide?
Retatrutide is an experimental triple receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it represents the next generation beyond current weight loss drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro).
Key advantage: While semaglutide targets only GLP-1 receptors and tirzepatide targets GLP-1 + GIP, retatrutide adds glucagon receptor activation for potentially superior weight loss and metabolic benefits. For more weight loss options, see our complete peptides guide.
Current Status
Phase 3 clinical trials — currently recruiting patients worldwide
Not FDA-approved — still investigational, not available by prescription
Research compound — available through research chemical suppliers
Expected approval: 2026-2027 if trials succeed
Why Retatrutide Matters
Current GLP-1 drugs like Ozempic and Mounjaro have revolutionized obesity treatment, but retatrutide's Phase 2 results suggest it could be significantly more effective:
Greater weight loss: Up to 24% body weight reduction at highest doses
Universal response: 100% of participants at highest dose achieved ≥5% weight loss
Metabolic benefits: Improved liver fat, insulin sensitivity, and lipid profiles
Novel mechanism: Glucagon activation adds energy expenditure to appetite suppression
Triple Agonist Mechanism
Retatrutide's unique triple receptor activation creates synergistic effects for weight loss and metabolic health:
Unique advantage: No other approved weight loss drug targets glucagon
The triple advantage: GLP-1 + GIP reduce appetite and improve glucose control, while glucagon activation increases energy expenditure — creating a powerful combination for weight loss from both reduced intake AND increased burning.
Clinical Trial Results
Phase 2 Trial (NEJM 2023)
The landmark Phase 2 study followed 338 obese adults for 48 weeks, testing different retatrutide doses:
Dose (Weekly)
Average Weight Loss
≥5% Weight Loss
≥15% Weight Loss
Placebo
-2.1%
27%
3%
1mg
-7.2%
75%
25%
4mg
-12.9%
92%
67%
8mg
-17.5%
96%
83%
12mg
-24.2%
100%
91%
Liver Fat Reduction (PMC12190491)
Retatrutide showed remarkable effects on liver health:
Hepatic fat reduction: Average 50-70% reduction from baseline
Normal liver fat: 89-93% of participants achieved <5% liver fat at 48 weeks
Dose-dependent: Higher doses produced greater liver fat reduction
Clinical significance: May reverse non-alcoholic fatty liver disease (NAFLD)
Metabolic Improvements
HbA1c reduction: 0.8-1.3% decrease from baseline
Blood pressure: 5-10 mmHg reduction in systolic BP
Lipid profile: Significant improvements in triglycerides and HDL
Inflammatory markers: Reduced CRP and other inflammatory indicators
Universal response: The most striking finding was that 100% of participants receiving 12mg achieved clinically significant (≥5%) weight loss — no other weight loss drug has shown universal efficacy.
Dosing Protocol
Based on the Phase 2 clinical trial protocol, retatrutide requires gradual dose escalation to minimize side effects:
NEJM Phase 2 Titration Schedule
Weeks
Dose (Weekly)
Notes
1-4
1mg
Starting dose, assess tolerance
5-8
2mg
First escalation if well-tolerated
9-12
4mg
Therapeutic dose for many users
13-16
6mg
Higher efficacy, monitor side effects
17-20
8mg
Near-maximal efficacy
21+
12mg
Maximum studied dose
Practical Dosing Guidelines
Injection schedule: Once weekly, same day each week
Injection site: Subcutaneous in abdomen, thigh, or upper arm
Timing: Any time of day, with or without food
Storage: Refrigerate vials, allow to reach room temperature before injection
Dose Adjustment Guidelines
Skip escalation if: Significant nausea, vomiting, or GI intolerance
Stay at current dose: Until side effects resolve (usually 1-2 weeks)
Reduce dose if: Persistent severe side effects that don't improve
Individual response: Some may achieve goals at 4-6mg, others need 8-12mg
Important: Never skip the titration schedule. Jumping to higher doses increases risk of severe nausea, vomiting, and gastroparesis. Slow escalation is essential for tolerance.
Benefits & Effects
Weight Loss Benefits
Rapid appetite suppression: Noticeable within days of starting
Sustained weight loss: Continues throughout treatment period
Reduced food cravings: Especially for high-calorie, processed foods
Smaller portion sizes: Natural reduction in meal size
Less food preoccupation: Reduced mental focus on food and eating
Metabolic Health
Improved insulin sensitivity: Better glucose control and HbA1c
Liver fat reduction: May reverse NAFLD and improve liver enzymes
Universal response: 100% responder rate at highest dose
Energy expenditure: Glucagon activation increases metabolic rate
Liver benefits: Superior hepatic fat reduction vs other drugs
Patient reports: Users describe retatrutide as more effective than previous GLP-1 drugs, with better appetite control and less plateau effect during treatment.
Side Effects
Like all GLP-1 class drugs, retatrutide commonly causes gastrointestinal side effects, especially during dose escalation:
Common Side Effects (>10% of users)
Nausea: Most common, usually improves after 1-2 weeks at stable dose
Diarrhea: Often mild to moderate, may be dose-limiting
Vomiting: More common with rapid dose escalation
Constipation: Due to slowed gastric motility
Abdominal pain: Usually mild, related to GI slowing
Decreased appetite: Intended effect but can be excessive
Less Common Side Effects (1-10%)
Injection site reactions: Redness, swelling, itching
Fatigue: May be related to rapid weight loss
Dizziness: Possible blood pressure or blood sugar changes
Headache: Usually mild and temporary
Gastroparesis: Severe stomach paralysis (rare but serious)
Serious Concerns
Pancreatitis: Rare but potentially life-threatening
Thyroid tumors: Theoretical risk based on animal studies
Kidney problems: Dehydration from nausea/vomiting
Hypoglycemia: Especially if combined with other diabetes drugs
Red flags: Seek medical attention for severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of pancreatitis (severe stomach pain radiating to back).
Retatrutide vs Semaglutide vs Tirzepatide
Factor
Retatrutide
Semaglutide (Ozempic)
Tirzepatide (Mounjaro)
Receptor Targets
GLP-1 + GIP + Glucagon
GLP-1 only
GLP-1 + GIP
Max Weight Loss
24.2% (12mg)
15% (2.4mg)
21% (15mg)
Responder Rate (≥5%)
100% (12mg dose)
86% (2.4mg dose)
96% (15mg dose)
Dosing Frequency
Weekly
Weekly
Weekly
FDA Approval
Phase 3 trials
Approved 2021
Approved 2022
Nausea Rate
58% (dose-dependent)
44% (dose-dependent)
31% (dose-dependent)
Liver Fat Reduction
50-70% reduction
30-40% reduction
40-50% reduction
Energy Expenditure
Increases (glucagon)
No direct effect
Minimal effect
When to Choose Retatrutide
Maximum weight loss needed: When 24% weight loss advantage matters
Previous GLP-1 plateau: When semaglutide or tirzepatide stopped working
Liver health priority: When fatty liver is a major concern
Research participation: Willing to use investigational compound
When to Choose Established Options
Insurance coverage: Semaglutide and tirzepatide may be covered
Long-term safety data: More human experience with approved drugs
Medical supervision: Easier to find prescribing physicians
Lower side effect tolerance: May prefer tirzepatide's lower nausea rate
Retatrutide Dosing Calculator
Calculate your retatrutide doses, injection volumes, and cycle planning with our comprehensive calculator:
How much weight can I expect to lose with retatrutide?
Based on clinical trials, average weight loss ranges from 7% at 1mg weekly to 24% at 12mg weekly after 48 weeks. Individual results vary based on starting weight, diet, exercise, genetics, and adherence to treatment.
Is retatrutide better than Ozempic or Mounjaro?
Clinical trials suggest retatrutide produces greater weight loss (24% vs 15% for semaglutide, 21% for tirzepatide) with universal responder rates. However, it's still investigational and has higher nausea rates than tirzepatide.
What's the difference between retatrutide and other GLP-1 drugs?
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) vs semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP). The glucagon activation increases energy expenditure, potentially explaining its superior weight loss results.
How long does it take to see results?
Appetite suppression typically begins within 3-7 days. Noticeable weight loss usually starts by week 2-4. Significant weight loss becomes apparent by months 2-3, with peak effects around 6-12 months of treatment.
Can I start at a higher dose to lose weight faster?
No. Starting at high doses dramatically increases risk of severe nausea, vomiting, and gastroparesis. The titration schedule is essential for tolerance. Rapid dose escalation often leads to treatment discontinuation.
What happens when I stop retatrutide?
Weight regain is common when stopping GLP-1 drugs, though the rate varies. Some maintain weight loss through lifestyle changes, while others regain 50-70% of lost weight within 12 months. Long-term lifestyle changes are crucial for maintenance.
Is it safe to use retatrutide if it's not FDA-approved?
Using investigational compounds involves risks. While Phase 2 trials show promising safety data, long-term effects are unknown. Consider working with a healthcare provider experienced in research peptides for monitoring and risk assessment.
Can I combine retatrutide with other weight loss drugs?
Combining with other GLP-1 drugs is not recommended due to additive side effects. Combinations with stimulants, orlistat, or other weight loss drugs should only be done under medical supervision due to potential interactions and increased side effect risk.